Skip To Main Content
Yinghui Tong on Muck Rack

Yinghui Tong

As seen in: PLOS ONE
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yinghui

Contact Yinghui, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cost-effectiveness of PARP inhibitors in malignancies: A systematic review

|
By Haiying Ding, Chaoneng He, Yinghui Tong, Qilu Fang
| paperity.org
PLOS ONE, Dec 2022 This is a preview of a remote PDF: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0279286&type=printable Haiying Ding, Chaoneng He, Yinghui Tong, Qilu Fang, Xiufang Mi, Lingya Chen, Wenxiu Xin, Luo Fang. , PLOS ONE, 2022, Volume 17, Issue 12, DOI: 10.1371/journal.pone.0279286
Open in Who Shared View Duplicates (486) Issue with article?

Cost-effectiveness of PARP inhibitors in malignancies: A systematic review

|
By Haiying Ding, Yinghui Tong, Chaoneng He
| PLOS ONE
Cost-effectiveness outcomes Cost-effectiveness outcomes are summarized in Table 1 and S3 Table. Among 17 studies on the cost-effectiveness of PARPi maintenance therapy for ovarian cancer, eight were for platinum-sensitive recurrent ovarian cancer [16–20, 31, 35, 39] and nine were for first-line platinum-based chemotherapy for newly diagnosed ovarian cancer [22–26, 28, 34, 37, 38].
Open in Who Shared Issue with article?

Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review

|
By Haiying Ding, Wenxiu Xin, Yinghui Tong
| PLOS
Loading metrics Open Access Peer-reviewed Research Article Haiying Ding , Wenxiu Xin , Yinghui Tong, Jiao Sun, Gaoqi Xu, Ziqi Ye, Yuefeng Rao Haiying Ding, Wenxiu Xin, Yinghui Tong, Jiao Sun, Gaoqi Xu, Ziqi Ye, Yuefeng Rao Published: September 2, 2020 https://doi.org/10.1371/journal.pone.0238536 Figures Abstract Background Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC) have been rapidly evolving.
Open in Who Shared Issue with article?
See all 3 articles